Guillermo Amescua1, Alejandro Arboleda, Neda Nikpoor, Heather Durkee, Nidhi Relhan, Mariela C Aguilar, Harry W Flynn, Darlene Miller, Jean-Marie Parel. 1. *Department of Ophthalmology, Anne Bates Leach Eye Hospital, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL; †Department of Ophthalmology, Ophthalmic Biophysics Center, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL; and ‡Department of Ophthalmology, Ocular Microbiology Laboratory, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL.
Abstract
PURPOSE: To evaluate the efficacy of rose bengal PDAT for the management of a patient with multidrug-resistant Fusarium keratoplasticum keratitis unresponsive to standard clinical treatment. METHODS: This case report presents a clinical case of F. keratoplasticum keratitis not responsive to standard medical care. In vitro studies from patients culture isolated responded to rose bengal PDAT. Patient received two treatments with rose bengal 0.1% and exposure to green light with a total energy of 2.7 J/cm. RESULTS: In vitro results demonstrated the efficacy of rose bengal PDAT a multidrug-resistant F. keratoplasticum species. There was complete fungal inhibition in our irradiation zone on the agar plates. In the clinical case, the patient was successfully treated with 2 sessions of rose bengal PDAT, and at 8-month follow-up, there was neither recurrence of infection nor adverse effects to report. CONCLUSIONS: Rose bengal PDAT is a novel treatment that may be considered in cases of aggressive infectious keratitis. Further studies are needed to understand the mechanisms of PDAT in vivo.
PURPOSE: To evaluate the efficacy of rose bengal PDAT for the management of a patient with multidrug-resistant Fusariumkeratoplasticum keratitis unresponsive to standard clinical treatment. METHODS: This case report presents a clinical case of F. keratoplasticum keratitis not responsive to standard medical care. In vitro studies from patients culture isolated responded to rose bengal PDAT. Patient received two treatments with rose bengal 0.1% and exposure to green light with a total energy of 2.7 J/cm. RESULTS: In vitro results demonstrated the efficacy of rose bengal PDAT a multidrug-resistant F. keratoplasticum species. There was complete fungal inhibition in our irradiation zone on the agar plates. In the clinical case, the patient was successfully treated with 2 sessions of rose bengal PDAT, and at 8-month follow-up, there was neither recurrence of infection nor adverse effects to report. CONCLUSIONS:Rose bengal PDAT is a novel treatment that may be considered in cases of aggressive infectious keratitis. Further studies are needed to understand the mechanisms of PDAT in vivo.
Authors: Ali Fadlallah; Hong Zhu; Samer Arafat; Irene Kochevar; Samir Melki; Joseph B Ciolino Journal: Invest Ophthalmol Vis Sci Date: 2016-12-01 Impact factor: 4.799
Authors: Francisco Halili; Alejandro Arboleda; Heather Durkee; Mukesh Taneja; Darlene Miller; Karam A Alawa; Mariela C Aguilar; Guillermo Amescua; Harry W Flynn; Jean-Marie Parel Journal: Am J Ophthalmol Date: 2016-03-23 Impact factor: 5.258
Authors: Dalia G Said; Mohamed S Elalfy; Zisis Gatzioufas; Ehab S El-Zakzouk; Mansour A Hassan; Mohamed Y Saif; Ahmed A Zaki; Harminder S Dua; Farhad Hafezi Journal: Ophthalmology Date: 2014-02-25 Impact factor: 12.079
Authors: Daniel Cherfan; E Eri Verter; Samir Melki; Thomas E Gisel; Francis J Doyle; Giuliano Scarcelli; Seok Hyun Yun; Robert W Redmond; Irene E Kochevar Journal: Invest Ophthalmol Vis Sci Date: 2013-05-13 Impact factor: 4.799
Authors: Jaime D Martinez; Andrea Naranjo; Guillermo Amescua; Sander R Dubovy; Alejandro Arboleda; Heather Durkee; Mariela C Aguilar; Harry W Flynn; Darlene Miller; Jean-Marie Parel Journal: Cornea Date: 2018-10 Impact factor: 2.651
Authors: Christopher Donovan; Eduardo Arenas; Ramesh S Ayyala; Curtis E Margo; Edgar M Espana Journal: Surv Ophthalmol Date: 2021-08-20 Impact factor: 6.197
Authors: Andrea Naranjo; Alejandro Arboleda; Jaime D Martinez; Heather Durkee; Mariela C Aguilar; Nidhi Relhan; Neda Nikpoor; Anat Galor; Sander R Dubovy; Roger Leblanc; Harry W Flynn; Darlene Miller; Jean-Marie Parel; Guillermo Amescua Journal: Am J Ophthalmol Date: 2019-09-05 Impact factor: 5.258
Authors: Jeffrey C Peterson; Esdras Arrieta; Marco Ruggeri; Juan D Silgado; Keenan J Mintz; Ernesto H Weisson; Roger M Leblanc; Irene Kochevar; Fabrice Manns; Jean-Marie Parel Journal: Biomed Opt Express Date: 2020-12-10 Impact factor: 3.732
Authors: Loretta B Szczotka-Flynn; Joseph P Shovlin; Cristina M Schnider; Barbara E Caffery; Eduardo C Alfonso; Nicole A Carnt; Robin L Chalmers; Sarah Collier; Deborah S Jacobs; Charlotte E Joslin; Abby R Kroken; Carol Lakkis; Eric Pearlman; Oliver D Schein; Fiona Stapleton; Elmer Tu; Mark D P Willcox Journal: Optom Vis Sci Date: 2021-03-01 Impact factor: 2.106